Uniting TCE Leaders to Optimise Target Selection & Innovate Cell Engager Design to Accelerate Transformative Immunotherapies from Research Towards Clinical Approval
Mitigating on-target, off-tissue toxicity while maintaining efficacy remains a core challenge for the T-cell engager (TCE) field. Yet, with a surge in investment, collaboration and promising clinical data, the space continues to gain momentum. From Cytospire Therapeutics’ oversubscribed £61 million Series A financing to the LabGenius and LG Chem partnership advancing AI-driven cancer antibodies, Europe’s immunotherapy landscape is accelerating rapidly and unlocking new opportunities.
Yet significant challenges remain. Despite encouraging efficacy signals, the field continues to grapple with on-target, off-tumour toxicity, limited durability of response, T-cell exhaustion, resistance mechanisms, and the identification of clean, disease-specific targets.
Solving these challenges will require greater collaboration between discovery scientists, translational researchers, clinical developers, and industry leaders.
This is why the 2nd T-Cell Engager Therapeutics Summit Europe returns to London as Europe's only dedicated industry-led meeting focused exclusively on advancing T-cell engager development. Across three focused days, gain practical insight into how leading organisations are overcoming the scientific, translational, and clinical bottlenecks that stand between promising assets and patient impact.
What You'll Gain - Wherever You Are in Development
Discovery & Early Research
Advance your next generation of T-cell engagers with insights into target identification, antigen selection, molecular engineering, multispecific formats, and strategies to enhance tumour specificity while minimising toxicity.
Translational & Preclinical Development
Strengthen your path to the clinic with case studies exploring biomarker strategies, translational models, safety assessment, pharmacology, and approaches for predicting and mitigating adverse events earlier in development.
Clinical Development & Medical Leadership
Learn how leading organisations are optimising dose selection, patient stratification, safety monitoring, and trial design to improve efficacy, manage toxicity, and generate meaningful clinical outcomes.
Next-Generation TCE Innovation
Explore emerging solutions to some of the field's biggest challenges, including overcoming T-cell exhaustion, extending durability of response, unlocking novel targets, and expanding the potential of T-cell engagers beyond oncology.
With world-class speakers from GSK, AstraZeneca, Cullinan Therapeutics, Immunocore, Enara Bio, Roche, Genmab and more, this is your premier opportunity to stay at the forefront of T-cell engager development.
Struggling with On-Target/Off-Tissue Toxicity?
If so, Join the Unmissable Pre-Conference Workshop Day
I hope to use this meeting to exchange practical insights on next‑generation TCE design, including improving performance in low‑antigen and heterogeneous tumours. I’m particularly interested in how approaches like co‑stimulation, conditional activation, and multi-specific formats translate into real clinical outcomes.
I also value the chance to engage with peers across the pipeline, from discovery through to the clinic. These discussions are important for challenging assumptions, highlighting shared bottlenecks, and identifying where closer collaboration could help move safer, more effective TCE therapies forward.
Duncan Howie, Director, Cell & Immunobiology, Enara Bio
Participating in the 2nd T-Cell Engager Therapeutics Summit Europe is a valuable opportunity to shape the field while learning from peers addressing similar challenges. It enables open exchange on overcoming barriers in serious diseases, refining precision and conditional designs, and building collaborations that accelerate impact. For me, it is about coming together to translate cutting-edge science into meaningful progress for patients.
Marcela Guzmán Ayala, Senior Director & Head, In Vitro Pharmacology, Molecular Partners AG
What makes this meeting especially valuable is its ability to connect scientific innovation with practical development strategy. In oncology, the field has accepted certain risks because of the severity of disease, but that framework does not simply carry over into autoimmune indications. Participating in this meeting is valuable because it creates space for a more mature conversation about what needs to change - in how we assess risk, interpret preclinical data, engage with regulators, and define appropriate dosing strategies. These are the discussions that will determine whether the promise of T cell engagers can be translated safely and credibly to a broader patient population.
Mahnoush Bahjat, Associate Director, Immunology Safety, AstraZeneca
Explore the Full Event Guide
- 24+ expert speakers from pioneering biotech and large pharma, including GSK, Cytospire Therapeutics, AstraZeneca, Cullinan Therapeutics, T-Cypher Bio, Immunocore, Synolo Therapeutics, Roche and more
- Gain in-depth data-driven insights into achieving selective targeting of tumour-specific antigens, novel engineering approaches and emerging opportunities for TCEs in oncology and autoimmune diseases
- 5 interactive workshops and panel discussions to solve challenges in resistance, T cell exhaustion and on-target/off-tissue tissue to accelerate more efficacious and potent TCEs towards the clinic
Attending Companies Include
Explore Related Events
Explore the Agenda
Discover the latest breakthroughs shaping TCE development, from novel target selection strategies and innovative engager engineering approaches to translational and clinical insights. Gain exclusive insights from industry leaders during data-driven presentations, interactive workshops and expert panel discussions.
Partner With Us
Showcase your solutions alongside other leading solution providers to a community dedicated to cutting-edge TCE innovation. Position your brand at the heart of the biopharma deals and partnerships defining oncology and autoimmune disease pipelines.
Join TCE Experts
Connect with TCE innovators and engage in the hottest conversations propelling safe and efficacious TCE development. During the dedicated networking sessions, make critical connections, and build meaningful collaborations.